Heartflow Q2 2025 Earnings Report

Heartflow EPS Results

• Actual EPS: -$1.46
• Consensus EPS: -$0.20
• Beat/Miss: Missed by -$1.26
• One Year Ago EPS: N/A

Heartflow Revenue Results

• Actual Revenue: $43.42 million
• Expected Revenue: $43.20 million
• Beat/Miss: Beat by +$220.00 thousand
• YoY Revenue Growth: N/A

Heartflow Announcement Details

• Quarter: Q2 2025
• Date: 9/19/2025
• Time: After Market Closes
• Conference Call Date: Friday, September 19, 2025
• Conference Call Time: 8:30AM ET

Heartflow (NASDAQ:HTFL) (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact. The output is intended to support diagnostic decision-making—helping to triage patients, reduce unnecessary invasive coronary angiography, and guide treatment planning such as the need for percutaneous coronary intervention or medical management. The company positions its technology as a tool for cardiology, radiology and emergency-department pathways where non-invasive assessment of coronary physiology can improve patient care.

The company works with hospitals, imaging centers and health systems and has expanded its commercial presence beyond the U.S. into multiple international markets. HeartFlow pursues collaborations with clinical research groups and payers to support adoption and reimbursement, and it emphasizes evidence from clinical studies demonstrating the clinical utility of physiology-based CT analysis. The business model centers on a software-as-a-service delivery of advanced image analysis and clinical reporting to support precision diagnostics in cardiovascular care.